WIMR strengthens Board Committees with new appointments

WIMR is pleased to announce several recent appointments to Board Committees, strengthening our expertise across governance, risk and commercialisation.

Manisha Goyal has joined the Board Audit and Risk Committee and has commenced as the inaugural Chair of the WIMR Cybersecurity Governance Board Working Group.
Manisha is an experienced C-suite and board-level executive overseeing legal, governance, enterprise risk management, regulatory compliance and internal control frameworks across technology and data businesses. She is currently Chief Legal Officer of SiteMinder Ltd, a high-growth listed global technology company.

Her previous roles include Chief Strategy and Risk Officer at MTData (a subsidiary of Telstra Group), Managing Director of muru-D, and General Counsel and Company Secretary at Quantium. Manisha has also held board and committee roles, including Chair of the Audit and Risk Committee at Silicon Quantum Computing, and board roles with muru-D and Bipolar Australia.

Dr Christian Toouli has joined the IP and Commercialisation Committee.
Christian is CEO and Managing Director of FivepHusion, a biotechnology company developing next-generation cancer therapeutics to improve outcomes and quality of life for adult and paediatric patients. He has more than 25 years’ experience across cancer research, drug development, business development and commercialisation, and has co-founded two biotechnology companies.

He is actively engaged in supporting the Australian biotech sector, serving on advisory committees for AusBiotech and BioNSW, regularly speaking at university and industry forums, and mentoring biomedical research students. He holds a PhD from the University of Sydney and is a Graduate of the Australian Institute of Company Directors.

Dr Kerstin Schütz has joined the IP and Commercialisation Committee.
Kerstin is an executive and non-executive director with deep expertise in translating scientific breakthroughs into real-world impact. With a PhD in Biophysics and an MBA from Melbourne Business School, she brings a strong combination of scientific insight and commercial strategy across biotechnology, MedTech and pharmaceutical innovation.

She works with global pharmaceutical companies, high-growth start-ups and national innovation programs, and supports early-stage ventures through Australia’s Industry Growth Program. Kerstin contributes to national investment, commercialisation and advisory committees across Australia’s medical research and innovation ecosystem.

Board Chair, Michael Rose AM, said “these appointments strengthen WIMR’s governance and its capacity to translate research into real-world impact. The breadth of experience across commercialisation, risk and innovation will support the Institute’s continued growth and its role within Western Sydney and beyond.”